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Abstract
Background More than 90% of vitamin D synthesis is dependent on UV exposure. Photosensitive disorders such
as lupus erythematosus, protoporphyria and xeroderma require strict sun avoidance, and vitamin D deficiency has
been demonstrated in these patients. Melanoma patients are also instructed to avoid sun exposure and may hence
be expected to be vitamin D deficient.
Materials and methods Winter and summer vitamin D levels were compared in a group of melanoma patients
(n = 61) and age- and phototype-matched controls (n = 53) without photosensitive disorders.
Results Oral supplementary vitamin D intake was reported in 32.7% of the melanoma patients and in 15.1% in the
control group. Despite oral supplementation, only 25% of the melanoma patients and the controls presented with
vitamin D levels of 30 ng ⁄ mL or higher. In non-supplemented subjects in the melanoma and control groups,
respectively, mean winter vitamin D levels were below the recommended threshold at 12.6 ng ⁄ mL vs. 13.2 ng ⁄ mL,
respectively, but not statistically different. These values increased significantly in both groups during the summer to
24.6 and 23.8 ng ⁄ mL respectively.
Conclusion Unexpected, significant increases in vitamin D levels were seen in melanoma patients during summer,
suggesting non-adherence with photoprotective measures and reflecting a heliophilic behaviour. Vitamin D
supplementation is recommended in melanoma patients during both winter and summer.
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Vitamin D deficiency is a common and widespread condition in
children and adults.1,2 Most experts recommend a level of
30 ng ⁄ mL or higher.2 Vitamin D deficiency increases the risk for
phosphocalcic disorders such as osteopenia, osteoporosis, osteo-
malacia, muscle weakness, growth retardation, skeletal deformities
and bone fractures.2,3 Recent research has revealed the importance
of vitamin D in a range of conditions such as cardiovascular dis-
ease including arterial hypertension,4 various malignancies,5 multi-
ple sclerosis,6 increased susceptibility to some infectious diseases,7
psychiatric disorders8 and autoimmune diseases.2
UV-B radiation is responsible for meeting 90% of the body’s
vitamin D requirements.2,9 Strict photoprotection is recom-
mended for patients with photosensitive disorders, renal transplant
recipients,10 skin cancer patients10 and for those taking photo-
sensitizing drugs. The same recommendations are valuable for
melanoma patients,11 although some contradiction exists.12
Consequently, evidence of low vitamin D levels have been found
in patients with xeroderma pigmentosum,10,13 Gorlin’s syndrome,
lupus eryhematosus,14 HIV-infection, erythropoietic protoporphy-
ria,15 as well as in renal transplant recipients.17 Low vitamin D
levels may also be expected in melanoma patients.
This prospective, single-centre study compared the seasonal
variations of vitamin D levels in melanoma patients with those in
healthy, age-matched, non-photosensitive controls.
Materials and methods
The study was performed according to the Helsinki Protocol
(2000) and approved by the local ethics committee. Outpatient
melanoma patients (n = 61) were included irrespective of their
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melanoma staging. The healthy control group (n = 53) comprised
age- and phototype-matched subjects. Patients with photosensitive
diseases, including discoid lupus erythematosis, subacute cutane-
ous lupus, chronic actinic dermatitis, polymorphous light erup-
tion, actinic prurigo and porphyria cutana tarda, and patients
receiving phototherapy or photosensitizing drugs were excluded.
Oral supplementary vitamin D intake and phototype was
recorded. Vitamin D levels were measured during the winter per-
iod (January and February) and during the summer period
(August and September). Levels of 25-OH vitamin D were deter-
mined using the Liaison 25-OH vitamin D total method (Diaso-
rin, Stillwater, MN, USA). In this study, the 30 ng ⁄ mL vitamin D
threshold was used.
Results
All melanoma patients and controls presented with phototypes II
or III. Oral supplementary vitamin D intake was reported in
32.7% (20 ⁄ 61) of the melanoma patients and in 15.1% (8 ⁄ 53) of
subjects in the control group. Irrespective of season, only 25% of
the orally supplemented melanoma patients and controls pre-
sented with vitamin D levels ‡30 ng ⁄ mL. Table 1 summarizes the
different patient categories, mean age, the number of patients, and
winter and summer vitamin D levels. The mean age of vitamin D-
supplemented melanoma patients and controls was higher
compared with non-supplemented patients at 63.7 and 59.6 years
vs. 43.7 and 47.2 years, respectively.
Winter and summer vitamin D levels were below recommended
levels (30 ng ⁄ mL) in non-vitamin D-supplemented and in vitamin
D-supplemented melanoma patients and controls (Fig. 1). No
statistical significant difference was observed between non-supple-
mented melanoma patients and controls with respect to vitamin
D levels (P < 0.0001). Vitamin D levels were higher in melanoma
patients and controls on oral vitamin D supplementation than in
non-supplemented subjects. Vitamin D levels increased signifi-
cantly during the summer period in non-supplemented melanoma
patients and controls. The mean increase in melanoma patients
was 12.0 ng ⁄ mL compared to 10.6 ng ⁄ mL in controls. The
changes in vitamin D levels are shown in Fig. 1.
Discussion
The low vitamin D levels observed in both melanoma patients and
healthy controls, irrespective of oral vitamin D supplementation
status, reflect the prevalence of vitamin D deficiency in the general
population. Oral vitamin D intake was reported in 32.7% of the
melanoma patients but only in 15.1% of the control group. This
difference probably reflects the increased awareness of the impor-
tance of vitamin D intake among both melanoma patients and ⁄ or
their doctors. Furthermore, supplementary vitamin D intake was
more prevalent in higher age groups, probably as a result of an
increased awareness of phosphocalcic disorders in this age group.
Vitamin D levels were expected to be low in the melanoma
patients, as commonly observed in patients with increased photo-
sensitivity.10,13,14 Surprisingly, there was a significant increase in
vitamin D levels during summer in the melanoma patients. These
differences could not be explained by high dietary intake of
Table 1 Patient distribution
Patient categories Mean age (years) Number Winter, mean (SD) Summer, mean (SD)
Melanoma with vit D3 63.7 n = 20 25.4 ND
Melanoma without vit D3 43.7 n = 41 12.6 (5.0) 24.6 (8.8)
Controls with vit D3 59.6 n = 12 29.8 ND
























Figure 1 Winter and summer vitamin D levels in melanoma
patients and healthy controls.
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vitamin D,1,2 nor by sun exposure of the face and the dorsum of
the hands only.16 An increase of this magnitude is most probably
due to full-body UV exposure.17 This suggests that melanoma
patients still display a heliophilic behaviour after diagnosis,
although patients usually deny this. The diagnosis of melanoma
has been shown to be associated with increased sun awareness and
protection.17 The use of sunscreen and protective clothing
increased and sunbed use decreased dramatically.18 However, in
the healthy population, health campaigns on photoprotection
seem to have had little impact on attitudes to sun exposure.18
Awareness of the risks of sun exposure is not always associated
with effective use of sun-avoiding measures. Only 54% of renal
transplant recipients recalled receiving advice on photoprotection
and only 30% were aware of the risks of photo exposure.19 Fur-
thermore, sun-protective measures were inadequate and the use of
sun barrier creams was inappropriate. Many patients fail to apply
sunscreen in adequate dosages, irrespective of body area. The
effective level of protection achieved is lower than the labelled
SPF, roughly by a factor of four.20 This study also showed that
adherence to photoprotection cannot be reliably assessed merely
by questioning the patients and suggested that vitamin D levels
could serve as indirect markers of compliance with sun-protective
measures in non-vitamin D-supplemented melanoma patients.
The results of this study provide a case for increased educational
efforts by dermatologists, healthcare professionals and public
health organizations to reduce heliophilic behaviour in melanoma
patients. Photoprotection should be adequate and adherence
assessed at every clinic visit.
Interestingly, significantly higher survival rates were reported in
a group of melanoma patients disrespecting anti-UV measures
compared with strictly sun-avoiding patients.21 Other recent
reports toned down the importance of UV radiance in melanoma
patients.12 The antiproliferative, antiangiogenic, antimetastatic and
apoptotic functions of vitamin D, mediated through VDR gene
encoded receptors, may account for the improved survival rate.
Nonetheless, guidelines for melanoma patients currently maintain
the recommendation of sun avoidance and oral vitamin D supple-
mentation.2 Vitamin D deficiency caused by sunscreen use should
not preclude adequate photoprotective behaviour.21 Indeed, this
study has shown that despite oral vitamin D supplementation,
only 25% of melanoma patients and controls presented with vita-
min D levels ‡30 ng ⁄ mL. In at-risk groups, a large dose should be
administered initially to restore vitamin D levels, followed by a
maintenance dose of 800 IU ⁄ day.2
Conclusion
This study showed an unexpected increase in vitamin D levels
during the summer period in non-vitamin D supplemented mela-
noma patients. This may reflect a persistent heliophilic behaviour
or inadequate use of sun-protective measures. Oral vitamin D
supplementation should be recommended and monitored in
melanoma patients.
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